Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809557 · ClinicalTrials.gov registry record · NA
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
A NA study of Metastatic Solid Tumor and Oncology, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05809557: Completed NA study of Metastatic Solid Tumor and Oncology, sponsored by Masonic Cancer Center, University of Minnesota.
NCT05809557 is a NA study of Metastatic Solid Tumor and Oncology that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 34 participants, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05809557, a NA study of Metastatic Solid Tumor and Oncology, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
Primary Outcome
Measured at the patient level as a binary outcome (yes/no) based on date of initial visit with the oncologist.
Conditions Studied
Interventions
- OTHER Chemotherapy toxicity tool
- OTHER Oncology Consultation
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2024-01-09 |
| Phase | NA |
What the finished NCT05809557 record still lists
NCT05809557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 192-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy toxicity tool is the first listed.
NCT05809557 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05809557 about?
NCT05809557 is a clinical study titled "EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity". This study will formally test the quality improvement intervention of an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity.
What is the current status of trial NCT05809557?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2023-01-09. Estimated completion is 2024-01-09.
What conditions does trial NCT05809557 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, Oncology, Chemotherapeutic Toxicity.
What interventions are being tested in trial NCT05809557?
The interventions under investigation include: Chemotherapy toxicity tool (OTHER), Oncology Consultation (OTHER).
Who is sponsoring clinical trial NCT05809557?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05809557 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05809557's enrollment target sits among peer trials
34 47th of 52 higher than 6 of 52 other Metastatic Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI